Physician profile
Kaiser G Lim
NPI 1457338725
$18,343.71
in general payments reported to CMS, 2019-2025
3 companies · $1,950 in 2025
The $1,950 reported for 2025 was more than what 75% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,127 · 2021: $4,875 · 2024: $4,391 · 2025: $1,950.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,341.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,341.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $7,316.25 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $7,127.46 | 2019 | |
| Glaxosmithkline, LLC. | $3,900.00 | 2024-2025 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaiser Lim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.